Massive Hydrothorax and Ascites as the Primary Manifestation of Infection With Clostridium difficile: A Case Report and Literature Review

Yujian Liang1†, Xiufang He2†, Ti Wang2, Yili Chen3, Huimin Huang1, Wen Tang1 and Yijuan Li*1

1 Department of Pediatrics, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, 2 Department of Pediatric Cardiology, Heart Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, 3 Department of Laboratory Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

Introduction: Clostridium difficile infection (cdi) often occurs with long-term and irregular use of antibiotics. Patients with tumors receiving both antibiotics and chemotherapy are at a high risk of cdi. The symptoms of cdi vary but can include diarrhea, hypovolemia, electrolyte imbalance, hypoproteinemia, toxic megacolon, gastrointestinal tract perforation, disseminated intravascular coagulation, sepsis, and other lethal complications. Here, we report a rare clinical manifestation associated with cdi in a child with lymphoma presenting with massive hydrothorax and ascites.

Case Presentation: A 6-year-old girl who was on chemotherapy for lymphoma presented with fever and was treated with intravenous broad-spectrum antibiotics 3 days before admission to our hospital. On the day before admission, she developed abdominal distension and diarrhea. After admission, broad-spectrum antibiotic therapy was initiated, and her hydrothorax and ascites were drained. An initial extensive microbiological evaluation revealed no pathogens, and laboratory tests and imaging studies of the pleural and peritoneal effusions revealed no evidence of cancer. The initial culture results for C. difficile were negative. The patient was diagnosed with CDI only after a positive test result for C. difficile toxin B gene and a repeated stool culture test revealed CDI. Intravenous antibiotics were suspended and replaced with oral vancomycin and Saccharomyces boulardii, which resulted in successful treatment and a good post-discharge outcome.

Conclusions: Massive hydrothorax and ascites are rare manifestations associated with CDI. CDI can occur in individuals with risk factors such as those undergoing broad-spectrum antibiotic therapy.

Keywords: Clostridium difficile infection, pediatric, large B-cell lymphoma, broad-spectrum antibiotics therapy, hydrothorax, ascites
INTRODUCTION

Clostridium difficile (CD) is an anaerobic gram-positive bacillus that is commonly detected in human and animal intestines and feces. Because of the proliferation of toxigenic C. difficile, C. difficile infection (CDI) is a commonly reported cause of nosocomial intestinal infection, accounting for an estimated 20–30% of cases (1). Toxigenic C. difficile produces at least two exotoxins: toxin A, an enterotoxin, and toxin B, a cytotoxin. These two toxins attack the membrane or actin skeleton of intestinal mucosal cells, leading to diarrhea and enteritis. Long-term exposure to broad-spectrum antibacterial medication, especially clindamycin, quinolones, and third-generation cephalosporins; severe underlying diseases; low immunity; and inflammatory bowel disease (such as ulcerative colitis) are reported risk factors for CDI (2). Immunosuppressed cancer patients are at a high risk of CDI. CDI symptoms are variable and include diarrhea, hypovolemia, electrolyte imbalance, hypoproteinemia, toxic megacolon, gastrointestinal tract perforation, disseminated intravascular coagulation, sepsis, and other lethal complications; however, massive hydrothorax and ascites as the main manifestations of CDI are very rare. This report describes a child with a lymphoma who developed CDI and presented with massive hydrothorax and ascites. This is the first report of CDI as the cause of massive hydrothorax and ascites in a child with a tumor.

This case report was approved by the Ethics Review Board of the First Affiliated Hospital, Sun Yat-sen University. The patient and her parents provided written informed consent to publication of this report.

CASE PRESENTATION

Clinical Presentation

A 6-year-old girl with lymphoma presented to our clinic with fever, diarrhea, abdominal distension, and shortness of breath, and was admitted. Before admission, she had received standard chemotherapy for a pediatric diffuse large B-cell lymphoma (3) at a specialist cancer hospital. The chemotherapy process is shown in Figure 1. Following the final chemotherapy session 10 days before admission, she had been in a period of post-chemotherapy myelosuppression, during which she developed a severe infection. After intravenous administration of cephalosporin antibiotics, she developed diarrhea and abdominal distension; however, no pathogen was identified. Her condition did not improve, and thus, the antibiotic therapy was discontinued. When the fever occurred during the period, she was administered intravenous vancomycin, imipenem, and carprofen for 3 days in a regional hospital, but her condition did not improve. Subsequently, she developed diarrhea with jelly-like stools (Figure 2), abdominal distension, nausea, vomiting, and shortness of breath. On Day 4, she was transferred to our clinic for further treatment.

Clinical Findings

Clinical examination revealed the following findings on admission: temperature, 37.5°C; heart rate, 130 beats/min;
respiratory rate, 52 breaths/min; respiratory moaning; neck and rib retraction; decreased bilateral breath sounds; shifting dullness (+); and mild edema of the lower limbs.

Diagnostic Focus and Assessment

Laboratory tests performed on the day of admission revealed a white blood cell count of $1.80 \times 10^{9}$/L (with 30.5% neutrophils); hemoglobin level of 6.9 g/dL; platelet count of $35 \times 10^{9}$/L; elevated C-reactive protein levels of 220 mg/L; decreased albumin levels of 2.8 g/dL; and elevated lactate dehydrogenase levels of 282 U/L. A stool examination was positive for fecal white blood cells but was negative for common bacteria and fungiculture, rotavirus, adenoviridae antigens, and C. difficile culture using ChromID and C. difficile agar (CDIF) (bioMérieux, Marcy L’Étoile, France) (4). Chest and abdominal computed tomography showed lung consolidations, pleural effusion, bilateral atelectasis, and massive ascites (Figure 3).

Based on these findings, she was diagnosed with severe pneumonia and diarrheal disease; however, the cause of the massive hydrothorax and ascites remained unclear. She continued to be treated with vancomycin, imipenem, and carprofen, and she was mechanically ventilated for progressive dyspnea. To relieve her dyspnea, we performed bilateral drainage of the thoracic and abdominal effusions, and drained clear, yellowish fluid. The results of the laboratory tests performed on the pleural and peritoneal effusions are given in Table 1.

With continued antibiotics and other therapy, her fever resolved. However, the amount of hydrothorax and ascites did not decrease significantly, and further tests were performed to investigate the cause of the persistent hydrothorax and ascites. A cytology test of the pleural and peritoneal fluid showed negative results. The chyle test, a qualitative test which uses ether to extract lipid and Sudan III to identify the presence of red fat globules microscopically, showed negative results, as did pathogen microbial high-throughput sequencing (PMseq). Bacteria, Mycobacterium tuberculosis, and fungal cultures of the pleural and peritoneal fluid were also negative. Due to the continuing diarrhea, we performed genetic testing using a real-time polymerase chain reaction assay for C. difficile toxin. This was positive for toxin B. To re-confirm the results, we re-cultured C. difficile using CDIF, and the test results were positive. Based on the above findings, we diagnosed CDI and hypothesized that the massive hydrothorax and ascites was a rare manifestation associated with the CDI.

Therapeutic Focus and Assessment

CDI is an antibiotic-related infection; therefore, we discontinued intravenous antibiotic therapy following the diagnosis, and treated the patient with oral vancomycin and Saccharomyces boulardii immediately. Furthermore, her oncologist suggested that chemotherapy for her lymphoma be suspended until she recovered from the CDI.

Follow-Up and Outcomes

Her stool frequency returned to normal after 3 days, her fever subsided after 1 week, her intestinal discomfort was relieved with the return to healthy stools, and her massive hydrothorax and ascites resolved completely. She was discharged after a 10-day oral course of vancomycin. She did not relapse during the 1-month follow-up period and resumed chemotherapy at the specialist cancer hospital.

DISCUSSION

CDI is commonly reported as a hospital-acquired infection. Patients with cancerous tumors who are receiving both antibiotics and chemotherapy have an increased risk of CDI. The incidence of CDI in hospitalized children in the United States is reported to have increased from 24.0/10,000 in 2003 to 58.0/10,000 in 2012, and the incidence in patients with cancer increased from 1.30/100 to 2.80/100 (11). According to data from a tertiary care hospital in China, the incidence of CDI in patients with hematologic tumors and bone marrow hematopoietic stem cell transplantation is 1.89/1000 and 3.69/1000, respectively (9). It has previously been established that CDI is closely associated with imbalances in the intestinal flora, and patients with cancer are at risk of developing imbalances in their intestinal flora. Rajagopala et al. (5) investigated the intestinal flora of children with leukemia, and their results showed that the microbiota profiles of both the patient and control sibling groups were dominated by Bacteroides, Prevotella, and Faecalibacterium. At the genus level, both groups shared many
The clinical manifestations of CDI are diverse. Clinically, patients with mild infections may present with a single episode of diarrhea, which can be in the form of watery stools, green mucus stools, pus, and bloody stools. In severe cases, a patient is likely to defecate plaque-like false membranes, while jelly-like stools are rare. Severe infections often lead to fever, abdominal pain, bloating, diarrhea, and increased white blood cell counts accompanied by dehydration, hypoproteinemia, toxic megacolon, and sepsis. However, the presence of pleural and peritoneal effusions is a rare manifestation of CDI and may be misdiagnosed as cancerous effusions in patients with tumors. Most cases of CDI presenting with massive hydrothorax and ascites as the primary manifestation have been reported among immunodeficient adults, and reports in children are rare. A summary of the national and international studies (8, 10, 12–15) is listed in Table 2. Based on these studies, only eight patients had CDI that manifested as ascites, and only two patients had CDI manifesting as pleural effusions and ascites (one in a child, and one in an adult). The child developed CDI after the administration of amoxicillin for otitis media, and the clinical manifestations were chronic diarrhea (white mucus discharge), abdominal distension with ascites, massive right pleural effusion, and shock (12). The mechanism of massive hydrothorax and ascites due to CDI remains unclear; however, hypoalbuminemia, colonic inflammation with micro-perforation and infectious peritonitis, and toxin-mediated cytokines enhancing vascular permeability could be involved (8). Among the ten patients reported with CDI, nine had hypoproteinemia, which was reported to be severe in five patients. In our case, the child was immunosuppressed and had been exposed to broad-spectrum antibiotics, which are both risk factors for CDI. Therefore, we performed a C. difficile culture on admission using CDIF, which can isolate and identify C. difficile strains within 24 h with a high sensitivity (4). However, the C. difficile results were negative, which delayed the diagnosis. Given a high clinical suspicion for CDI, we re-cultured C. difficile using CDIF and performed genetic testing using a real-time polymerase chain reaction assay for C. difficile toxins, and both test results were found to be positive. The two main types of
TABLE 2 | Summary of case studies with CD infection presenting with hydrothorax and ascites as main symptoms.

| Study by            | Age | Primary disease                     | Antibiotics treatment before CDI/duration | Hydrothorax | Ascites | Antibiotic/duration | Outcome     |
|---------------------|-----|-------------------------------------|-------------------------------------------|-------------|---------|---------------------|-------------|
| Pang et al. (5)      | 71 y| Gastrointestinal bleeding due to cimithis | Ceftriaxone IV/14 d                        | –           | +       | Omidazole PO/14 d    | cured       |
| Shen et al. (6)      | 61 y| Ulcerative colitis/10 d after intestinal operation | Ampicillin IV/NG                          | –           | +       | Vancomycin PO/NG     | died        |
| Tsourous et al. (7)  | 60 y| Type 2 diabetes/P AOD/soft tissue infection combined osteomyelitis | Amoxicillin, clindamycin PO/40 d          | –           | –       | Vancomycin PO/NG     | cured       |
| Boaz et al. (9)      | 25 y| Oral cavity infection                | Clindamycin PO/10 d                       | +           | +       | Vancomycin PO/NG     | cured       |
| Pang et al. (5)      | 54 y| AIDS/pneumocystosis                 | SMX, RMP PO/7 m                           | –           | +       | Metronidazole PO/14d | cured       |
| Shen et al. (6)      | 48 y| Heroin IV usage/URI                 | Erythromycin NG/7 d                       | –           | +       | Metronidazole PO/14d | cured       |
| Tsourous et al. (7)  | 30 y| AIDS/P. aeruginosa pneumonia        | Cefazidime, gentamicin IV/NG              | –           | –       | Vancomycin PO/14d    | cured       |
| Boaz et al. (9)      | 33 y| AIDS                                | SMX, fluconazole NG/IV/NG                 | –           | +       | Metronidazole PO/14d | cured       |
| Shen et al. (6)      | 58 y| CAP                                 | Erythromycin NG/6d                        | –           | +       | Metronidazole PO/21d | cured       |
| Our case             | 2 y 6 m | Otitis media                           | Amoxicillin NG/10d                        | +           | +       | Vancomycin PO/14d    | relapsed    |
| Zwiener et al. (10)  | 6 y | Diffuse large B cell lymphoma        | Vancomycin, imipenem IV/3d                | +           | +       | Vancomycin PO/12d    | cured       |

CDI, Clostridium difficile infection; PAOD, peripheral arteriosclerotic occlusive disease; AIDS, acquired immune deficiency syndrome; URI, upper respiratory infection; CAP, community-acquired pneumonia; SMX, sulfamethoxazole; RMP, rifampicin; NG, not given; y, years; m, months; d, days; IV, intravenous.

laboratory diagnosis for CDI comprise: (i) a fecal sample positive for *C. difficile* toxin and (ii) endoscopy or histopathological examination findings indicating pseudomembranous enteritis. *C. difficile* culture cannot be used to distinguish whether the strain has produced toxins; however, toxin detection is key to the diagnosis of CDI. At present, toxin detection methods include cell cytotoxicity assay, toxigenic culture, enzyme-linked immunoassay, and gene detection. Because gene detection has advantages in terms of rapidity, sensitivity, and specificity, genetic testing was used for our patient, despite the high cost of the test. Therefore, it is important to repeat tests, especially using different methods, when there is a high clinical suspicion of CDI.

Early recognition of CDI is very important for its treatment, with timely suspension of the original antibiotics, administration of antibiotics against *C. difficile*, administration of medication to adjust the intestinal flora, and rehydration and maintenance of electrolyte balance all being crucial in treating CDI. Diarrhea usually stops 5–8 days after discontinuing the original antibiotic; however, it has been reported to last for 2–3 weeks or even 2 months in some cases (16). When antibiotics are necessary to treat the primary disease, antibiotics that induce CDI, especially cephalosporins, clindamycin, and quinolones, should be avoided; narrow-spectrum antibiotics with minimal side-effects on the intestinal flora should be prescribed and administered parenterally, and the course of antibiotics should be as short as possible. If the antibiotics that induced CDI cannot be replaced or discontinued, a course of antibiotics against CDI should be extended to 1 week after the antibiotics that induced the CDI are stopped (17). Administration of metronidazole or vancomycin for 10 days is the preferred antibiotic therapy against *C. difficile*. For children with severe CDI, the use of oral vancomycin has been found to be associated with fewer relapses compared with metronidazole (18). In addition, probiotics can be used to adjust the gut microbiota. A systematic review of 38 randomized controlled trials (>8,000 patients) showed that Brassaica yeasts have anti-toxin effects in addition to adjusting the intestinal flora and have a better therapeutic effect on CDI than other probiotics (19). The use of intravenous immunoglobulins remains controversial (20). To treat hydrothorax and ascites due to CDI, it is necessary to treat the primary disease and to perform puncture and drainage when necessary, consistent with treatment for hydrothorax and ascites due to other causes. For our patient, after we obtained the diagnosis of CDI, all intravenous antibiotics were discontinued, and we switched her to oral vancomycin and Brassaica yeasts, which contributed to diarrhea improvement and the resolution of her massive hydrothorax and ascites. Furthermore, her chemotherapy for lymphoma was suspended as chemotherapy may aggravate CDI (7).

To conclude, massive hydrothorax and ascites are rare manifestations associated with CDI. Cancer patients who receive both chemotherapy and antibiotics are at a high risk of CDI. When clinical suspicion for CDI is high, repeat testing is important for early diagnosis and treatment.

**DATA AVAILABILITY STATEMENT**

All datasets generated for this study are included in the article-supplementary material.
ETHICS STATEMENT

The studies involving human participants were reviewed and approved by The First Affiliated Hospital, Sun Yat-sen University. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

AUTHOR CONTRIBUTIONS

YL and XH are co-first author. YL conceptualized and designed the study, reviewed, and revised the manuscript. YL and XH are co-first author. YL conceptualized and designed the study, reviewed, and revised the manuscript. YL and XH carried out the initial analyses and drafted the initial manuscript. TW and HH were responsible for the treatment of the patient. YC and WT coordinated and supervised the data collection. All authors read and approved the final manuscript.

REFERENCES

1. Paredes-Sabja D, Shen A, Sorg JA. Clostridium difficile spore biology: sporulation, germination, and spore structural proteins. Trends Microbiol. (2014) 22:406–16. doi: 10.1016/j.tim.2014.04.003
2. Leffler DA, Lamont JT. Clostridium difficile infection. New Engl J Med. (2015) 372:1539–48. doi: 10.1056/NEJMra1403772
3. Sun XE, Zhen ZJ, Xia Y, Lin SX, Zhu J, Wang J, et al. Clostridium difficile infection: report of a severe case with unusual clinical signs in a young nurse. Dis Colon Rectum. (2013) 56:264–6. doi: 10.1007/bf02236993
4. Park KS, Ki CS, Lee NY. Isolation and identification of Clostridium difficile using ChromID C. difficile medium combined with gram staining and PRO disc testing: a proposal for a simple culture process. Ann Lab Med. (2015) 35:404–9. doi: 10.3343/alm.2015.35.4.404
5. Rajagopala SV, Yooseph S, Harkins DM, Moncera KJ, Zabokrtsky KB, Torralba MG, et al. Gastrointestinal microbial populations can distinguish pediatric and adolescent acute lymphoblastic leukemia (ALL) at the time of disease diagnosis. BMC Genomics. (2016) 17:635. doi: 10.1186/s12864-016-2965-y
6. Montassier E, Gastinne T, Vangay P, Al-Ghalith GA, Bruley des Varannes S, Massart S, et al. Chemotherapy-driven dysbiosis in the intestinal microbiome. Aliment Pharmacol Ther. (2015) 42:515–28. doi: 10.1111/apt.13302
7. Perez A, Shlomo IB, Nitzan O, Bonavina L, Schaffer PM, Schaffer M. Clostridium difficile infection: associations with chemotherapy, radiation therapy, and targeting therapy treatments. Curr Med Chem. (2016) 23:4442–9. doi: 10.2174/0929867323666161028162018
8. Zuckerman E, Kanel G, Ha C, Kahn J, Gottesman BS, Korula J. Low albumin gradient ascites complicating severe pseudomembranous colitis. Gastroenterol. (1997) 112:991–4. doi: 10.1053/gast.1997.v112.pm9014126
9. Gu SL, Chen YB, Lv T, Zhang XW, Wei QZ, Shen P, et al. Risk factors, outcomes and epidemiology associated with Clostridium difficile infection in patients with haematological malignancies in a tertiary care hospital in China. J Med Microbiol. (2015) 64:209–16. doi: 10.1099/jmm.0.000028
10. Pang LJ, Cui EB, Qu F. Cirrhotic gastrointestinal bleeding with Clostridium difficile infection: a case report. Infectious Dis Inform. (2015) 11:224–5.
11. Pant C, Deshpande A, Gilroy R, Olyaei M, Donskey CJ. Rising incidence of Clostridium difficile-related discharge among hospitalized children in the United States. Infect Control Hosp Epidemiol. (2016) 37:104–6. doi: 10.1017/ice.2015.234
12. Zwiener RJ, Belknap WM, Quan R. Severe pseudomembranous enterocolitis in a child: case report and literature review. Pediatr Infect Dis J. (1989) 8:876–82. doi: 10.1097/00006454-198912000-00010
13. Tsourouis G, Raftopoulos LG, Kafe EF, Manoliris EK, Makaritsis KP, Pinis SG. A case of pseudomembranous colitis presenting with massive ascites. Eur J Intern Med. (2007) 18:328–30. doi: 10.1016/j.ejim.2006.09.034
14. Shen B, Remui FH, Fazio VW. Fulminant Clostridium difficile-associated pockititis with a fatal outcome. Nat Rev Gastro Hepat. (2009) 6:492–5. doi: 10.1038/nrgastro.2009.105
15. Boaz A, Dan M, Charuzi I, Landau O, Aloni Y, Kyzer S. Pseudomembranous colitis: report of a severe case with unusual clinical signs in a young nurse. Dis Colon Rectum. (2000) 43:264–6. doi: 10.1007/bf02236993
16. Alvarez AM, Rathore MH. Clostridium difficile infection in children. Adv Pediatr. (2019) 66:263–80. doi: 10.1016/j.yapd.2019.03.010
17. Mullane KM, Miller MA, Weiss K, Lentnek A, Golan Y, Sears PS, et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis. (2011) 53:440–7. doi: 10.1093/cid/cir404
18. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al. Clinical practice guidelines for Clostridium difficile infection in children: 2017 update by the INFECTIONIOUS DISEASES SOCIETY of America (IDSA) and society for healthcare epidemiology of America (SHEA). Clin Infect Dis. (2018) 66:e1–48. doi: 10.1093/cid/cix1085
19. Madoff SE, Urququiag M, Alonso CD, Kelly CP. Prevention of recurrent Clostridiodes difficile infection: a systematic review of randomized controlled trials. Anaerobe. (2019) 61:102098. doi: 10.1016/j.anaerobe.2019.102098
20. Shah PJ, Vakil N, Kabakov A. Role of intravenous immune globulin in streptococcal toxic shock syndrome and Clostridium difficile infection. Am J Health Syst Pharm. (2015) 72:1013–9. doi: 10.2146/ajhp140359

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Liang, He, Wang, Chen, Huang, Tang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.